Q32 Bio Inc. (QTTB) Key Metrics
QTTB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $223.9M
- Enterprise value
- $183.2M
- P/E (TTM)
- 2.4
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 4.2 10-yr median 23.0
- Price / book
- 2.7 10-yr median 3.1
- EV / EBITDA
- 5.1
- Dividend yield
- —
- Beta
- −0.11
QTTB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsQTTB valuation Price multiples at each fiscal year-end price.
QTTB returns How much profit the business earns on the capital it uses.
QTTB per-share figures Results divided by the shares outstanding at year-end.
QTTB financial health Debt, liquidity and how easily interest is covered.
QTTB efficiency & capital use Working capital cycle and where the cash goes.
QTTB valuation history
QTTB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
QTTB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
QTTB cash returned to shareholders
QTTB price vs earnings per share
QTTB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $40.9M | $33.2M | $130.6M | $270.6M | $781.6M | — | — | — | — | — |
| Enterprise value | $7.9M | −$25.8M | $155.8M | $125.5M | $649.7M | — | — | — | — | — |
| P/E ratio | 1.4 | — | — | — | — | — | — | — | — | — |
| Price / sales | 0.8 | — | — | 40.7 | 23.0 | — | — | — | — | — |
| Price / book | 1.0 | 5.9 | — | 1.5 | 4.6 | — | — | — | — | — |
| EV / sales | 0.1 | — | — | 18.9 | 19.1 | — | — | — | — | — |
| EV / EBITDA | 0.3 | — | — | — | — | — | — | — | — | — |
| Earnings yield | 72.9% | −143.7% | −41.2% | −15.8% | −4.8% | — | — | — | — | — |
| Free cash flow yield | −82.0% | −204.0% | −14.3% | −5.0% | −14.3% | — | — | — | — | — |
| Share price at fiscal year-end | $3.32 | $3.44 | $10.94 | $22.68 | $65.52 | $203.22 | $372.60 | $402.48 | — | — |
| Per share | ||||||||||
| Revenue per share | $4.36 | $0.00 | $0.00 | $0.56 | $2.85 | — | — | — | — | — |
| Earnings per share | $2.42 | −$4.94 | −$4.51 | −$3.59 | −$3.15 | — | — | — | — | — |
| Operating cash flow per share | −$2.72 | −$7.01 | −$1.57 | −$0.92 | −$9.20 | — | — | — | — | — |
| Free cash flow per share | −$2.72 | −$7.02 | −$1.57 | −$1.13 | −$9.40 | — | — | — | — | — |
| Cash per share | $3.92 | $8.07 | $2.15 | $14.67 | $13.07 | — | — | — | — | — |
| Book value per share | $3.41 | $0.59 | −$15.33 | $14.92 | $14.22 | — | — | — | — | — |
| Tangible book value per share | $3.41 | $0.59 | −$15.33 | $14.92 | $14.22 | — | — | — | — | — |
| Capex per share | $0.00 | $0.01 | $0.00 | $0.21 | $0.20 | — | — | — | — | — |
| Debt per share | $1.25 | $1.96 | $4.26 | $2.51 | $2.01 | — | — | — | — | — |
| Shares outstanding | 12.3M | 9.7M | 11.9M | 11.9M | 11.9M | — | — | — | — | — |
| Change in shares outstanding | +27.5% | −19.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 125.1% | — | — | −24.6% | −20.5% | −56.6% | −45.7% | −37.7% | −56.7% | −107.3% |
| Return on invested capital (ROIC) | — | — | — | −87.8% | −182.8% | — | — | — | — | — |
| Return on assets (ROA) | 38.7% | −68.5% | −38.9% | −19.4% | −15.8% | −44.8% | −36.5% | −28.0% | −39.5% | −56.6% |
| Return on tangible assets | 48.3% | −51.7% | −114.2% | −18.7% | −17.7% | −48.8% | −33.5% | −21.5% | −21.8% | −56.6% |
| Free cash flow margin | −62.4% | — | — | −202.1% | −330.1% | — | — | — | — | — |
| Income quality (OCF / net income) | −1.12 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $15.3M | $18.9M | $50.8M | $29.9M | $23.9M | $15.4M | — | — | — | — |
| Cash & short-term investments | $48.3M | $78.0M | $25.6M | $175.0M | $155.9M | $217.4M | $262.4M | $214.7M | $129.7M | $11.4M |
| Net debt | −$33.0M | −$59.1M | $25.2M | −$145.1M | −$131.9M | −$202.0M | −$262.4M | −$214.7M | −$129.7M | −$11.4M |
| Debt / equity | 0.37 | 3.33 | — | 0.17 | 0.14 | 0.08 | — | — | — | — |
| Debt / assets | 0.25 | 0.20 | 1.08 | 0.13 | 0.11 | 0.06 | — | — | — | — |
| Net debt / EBITDA | −1.05 | — | — | — | — | — | — | — | — | — |
| Current ratio | 4.85 | 4.97 | 2.04 | 7.71 | 11.14 | 9.69 | 21.54 | 9.84 | 14.85 | 1.88 |
| Quick ratio | 4.85 | 4.97 | 2.04 | 7.63 | 11.10 | 9.69 | 21.54 | 9.84 | 14.85 | 1.88 |
| Interest coverage | 15.4 | -60.1 | -32.2 | — | — | — | — | — | — | — |
| Working capital | $43.7M | $65.4M | $14.6M | $158.5M | $174.7M | $196.9M | $254.2M | $199.2M | $122.7M | $5.6M |
| Invested capital | $9.1M | −$53.4M | −$157.7M | $32.9M | $37.7M | −$6.0M | −$3.9M | −$18.4M | −$31.4M | −$3.9M |
| Tangible asset value | $42.0M | $5.7M | −$182.9M | $178.0M | $169.7M | $196.0M | $258.5M | $196.4M | $98.3M | $7.5M |
| Net current asset value | $35.3M | −$4.8M | −$201.3M | $130.5M | $149.8M | $151.8M | $214.5M | $158.9M | $92.4M | $5.3M |
| Graham number | $13.63 | — | — | — | — | — | — | — | — | — |
| Graham net-net per share | $2.32 | −$0.86 | −$17.08 | $10.49 | $9.63 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | — | — | — | $17,470 | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | 0.4% | — |
| Capex / revenue | 0.0% | — | — | 37.4% | 7.1% | 138.2% | 1,310.5% | 468.6% | — | — |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | 30.2% | — |
| Capex / depreciation | 0.01 | 0.15 | 0.01 | 6.72 | 0.25 | 0.42 | 3.46 | 19.35 | 2.86 | 8.30 |
| Stock-based compensation / revenue | 9.8% | — | — | 18.6% | 2.2% | — | — | — | — | — |
| R&D / revenue | 35.6% | — | — | 538.5% | 88.1% | 3,715.5% | 5,366.0% | 900.9% | — | — |
| SG&A / revenue | 32.9% | — | — | 151.3% | 19.9% | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | 54.1 | 7.0 | 54.0 | 131.5 | 54.9 | — | — |
| Days of inventory on hand | — | — | — | 176.9 | 29.4 | — | — | — | — | — |
| Days payables outstanding | 1,805.4 | 2,419.7 | 1,793.2 | 266.9 | 135.5 | — | — | — | 915.3 | 1,360.3 |
| Cash conversion cycle (days) | — | — | — | -35.9 | -99.1 | — | — | — | — | — |
| Receivables turnover | — | 0.00 | 0.00 | 6.74 | 51.90 | 6.75 | 2.78 | 6.65 | — | 0.00 |
| Payables turnover | 0.20 | 0.15 | 0.20 | 1.37 | 2.69 | 0.00 | 0.00 | 0.00 | 0.40 | 0.27 |
| Inventory turnover | — | — | — | 2.06 | 12.41 | — | 0.00 | — | — | — |
| Asset turnover | 0.70 | 0.00 | 0.00 | 0.03 | 0.14 | 0.01 | 0.01 | 0.03 | 0.00 | 0.00 |
| Average receivables | — | $655,000 | $909,500 | $986,500 | $654,500 | $400,000 | $600,000 | $800,000 | — | $113,260 |
| Average payables | $1.9M | $3.2M | $2.5M | $1.9M | $3.5M | $3.7M | $9.2M | $9.1M | $1.7M | $893,673 |
| Average inventory | — | — | — | $1.3M | $769,000 | — | $1 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from QTTB's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
QTTB valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Q32 Bio traded at 1.4 times earnings. Based on the latest twelve months, the trailing P/E is 2.4. Q32 Bio earned a return on equity of 125.1% in fiscal 2025. It ended the year with $15.3 million of debt and $48.3 million in cash and short-term investments, a net cash position of $33.0 million.
See the QTTB income statement, the QTTB chart for price history, or the QTTB stock overview for the latest quote and news.
QTTB key metrics FAQ
What is Q32 Bio's P/E ratio?
Q32 Bio's trailing P/E ratio is 2.4 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was 1.4.
What is Q32 Bio's EV/EBITDA?
Q32 Bio's enterprise value was 0.3 times EBITDA at the end of fiscal 2025 (enterprise value $7.9 million, EBITDA $31.3 million); the current EV/EBITDA is 5.1.
What is Q32 Bio's return on equity?
Q32 Bio's return on equity (ROE) was 125.1% in fiscal 2025: net income of $29.8 million on average shareholders' equity of $23.8 million.
How much debt does Q32 Bio have?
Q32 Bio had total debt of $15.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.37 and more cash than debt.
What is Q32 Bio's free cash flow yield?
Q32 Bio generated -$33.5 million of free cash flow in fiscal 2025, a free cash flow yield of −82.0% on its market value at year-end ($40.9 million).
What is Q32 Bio's current ratio?
Q32 Bio's current ratio was 4.85 at the end of fiscal 2025: current assets were 4.85 times current liabilities.